# EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

> **NCT02802592** · PHASE1,PHASE2 · TERMINATED · sponsor: **Johns Hopkins University** · enrollment: 4 (actual)

## Conditions studied

- Cardiac Surgery-CABG
- Cardiac Valve Replacement

## Interventions

- **DRUG:** Epogen
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02802592
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2016-06-15
- **Final completion:** 2017-02-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802592, "EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02802592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*